Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

SRPT

Sarepta Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 873303Held by 4 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$1.86B
Net Income FY2025
$(0.71B)
EPS (Basic, as reported)
$-7.13
Net Margin FY2025
-38.3%
ROE FY2025
-62.5%
Total Equity
$1.14B
Shares Out
106M
Business description

Sarepta Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2009–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 5 → 1,864 +93.1% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue51553013814566128441,1451,7881,864
Cost of revenue0————————(25)
Research & development(188)(167)(402)———————
Selling, general & administrative(84)(123)(208)(285)(318)(283)(451)(482)(558)(492)
General & administrative——————————
Total operating expenses(272)(326)(645)(1,086)(1,104)(1,162)(1,469)(1,511)(1,684)(2,898)
Operating income(267)(172)(344)(706)(564)(460)(536)(268)218(700)
Interest expense(2)(6)(34)(31)(60)(64)(53)(22)(18)(38)
Interest & investment income12773016363131
Other income (expense), net(1)123(19)(8)1141(154)(252)43(2)
Pre-tax income(267)(49)(363)(714)(553)(419)(690)(520)261(702)
Income tax expense—(2)(1)(1)(1)0(14)(16)(26)(11)
Net income(267)(51)(362)(715)(554)(419)(703)(536)235(713)
EPS — basic————($7.11)($5.15)($8.03)($5.80)$2.47($7.13)
EPS — diluted————($7.11)($5.15)($8.03)($5.80)$2.34($7.13)
Shares outstanding — basic (M)495966747881889295100
Shares outstanding — diluted (M)—59667478818892108100

Showing the latest 10 of 17 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.